Incyte Biosciences Denmark ApS: Financial statements 2016
CVR: 35818790
Source: annual report 2016, Danish Business Authority
01/01/2016 – 31/12/2016
Incyte Biosciences Denmark ApS (CVR 35818790) has filed annual accounts for 2016. In 2016, the company reported a gross profit of DKK 1,494,675 and a net result of DKK 25,251 compared with DKK 26,475 the year before. That is a decrease of 2.5% compared with the year before. Equity in the 2016 report amounted to DKK 107,132. The solvency ratio was 10.8%.
- Gross Profit
- DKK 1,494,675
- Profit/Loss
- DKK 25,251
- Equity
- DKK 107,132
- Total Assets
- DKK 994,962
Official annual report
Find more companies like Incyte Biosciences Denmark ApS
Build lead lists with filters on industry, geography, size and financials, and export straight to Excel.
Try the lead list generatorEvents in 2016
On July 18, 2016, the company changed its name from ARIAD PHARMACEUTICALS (DENMARK) ApS to Incyte Biosciences Denmark ApS.
Incyte Biosciences Denmark ApS has published its annual report for 2015. Gross profit came to DKK 1,532,406, and the net result was DKK 26,475.
About Incyte Biosciences Denmark ApS
Incyte Biosciences Denmark ApS is a Danish company of the type Anpartsselskab based in Frederiksberg C, founded in 2014. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named ARIAD PHARMACEUTICALS (DENMARK) ApS. The management consists of Ebba Cecilia Bröms. The board consists of Lee Jason Heeson (chair) and Ebba Cecilia Bröms. The company is owned by Incyte Biosciences International Sàrl. The company has 4 employees (2026). In 2025, the company reported a gross profit of DKK 6,696,586 and a net result of DKK 361,151 compared with DKK 368,873 the year before. Equity in the 2025 report amounted to DKK 2,328,496.